Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea

Exclusion Criteria

• •Patients less than 15 years old as of the index date (\<15 years old).
• •Patients who were treated with 5-ASA during the baseline period (i.e. 12-month prior to the index date).
• •Patients who were diagnosed with UC during the baseline period.
• •Patients who received steroids, immunosuppressants, or biologics during the baseline period.
• •* Steroid includes both oral medication and intravenous (IV) injection. The analysis will include the moderate- to high-dose of cumulative steroid use, which is defined as \>=30mg of prednisolone, \>= 50mg of methylprednisolone, or \>=50mg of hydrocortisone.
• •* Immunosuppressants is defined as at least one claim with Azathioprine or 6-Mercaptopurine.
• •* Biologics is defined as at least one claim with Infliximab, Adalimumab, Ustekinumab, Vedolizumab, Golimumab, or Tofacitinib.
• •Patients who were diagnosed with Crohn's disease at any time in the overall study period.
• •* Defined as a claim with relevant Crohn's disease code recorded as primary diagnosis during the baseline period or follow-up period (i.e. entire study period).